Market Cap | 617.94M | P/E | - | EPS this Y | -68.20% | Ern Qtrly Grth | - |
Income | -341.15M | Forward P/E | -2.62 | EPS next Y | 56.10% | 50D Avg Chg | - |
Sales | 258.82M | PEG | -0.03 | EPS past 5Y | - | 200D Avg Chg | -29.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | 30.00% | 52W High Chg | -68.00% |
Recommedations | 2.70 | Quick Ratio | 0.36 | Shares Outstanding | 363.49M | 52W Low Chg | 36.00% |
Insider Own | 29.96% | ROA | -51.38% | Shares Float | 210.21M | Beta | 1.04 |
Inst Own | 39.04% | ROE | - | Shares Shorted/Prior | 49.10M/47.43M | Price | 1.70 |
Gross Margin | -30.21% | Profit Margin | -131.70% | Avg. Volume | 6,738,357 | Target Price | 7.02 |
Oper. Margin | -205.86% | Earnings Date | Feb 27 | Volume | 4,214,797 | Change | -2.86% |
Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.
JP Morgan | Underweight | Nov 10, 22 |
Oppenheimer | Perform | Nov 9, 22 |
Piper Sandler | Neutral | Sep 19, 22 |
Roth Capital | Neutral | Aug 10, 22 |
JP Morgan | Neutral | Aug 26, 22 |
Piper Sandler | Neutral | May 25, 22 |
Roth Capital | Buy | Aug 6, 21 |
Oppenheimer | Outperform | Aug 6, 21 |
HC Wainwright & Co. | Buy | Aug 6, 21 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Kung Frank | Director Director | Sep 20 | Sell | 3.55 | 600,000 | 2,130,000 | 09/22/22 | |
Kung Frank | Director Director | Sep 15 | Sell | 3.87 | 3,298,776 | 12,766,263 | 109,460 | 09/19/22 |
KELSEY NICOLE | CHIEF LEGAL OFFICER-.. CHIEF LEGAL OFFICER- SECRETARY | Sep 02 | Sell | 2.87 | 5,019 | 14,405 | 58,314 | 09/07/22 |
ALVAREZ EDUARDO | CHIEF OPERATING OFFI.. CHIEF OPERATING OFFICER | Sep 02 | Sell | 2.87 | 22,421 | 64,348 | 351,914 | 09/07/22 |
Kieftenbeld Hermanus | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Sep 02 | Sell | 2.87 | 25,888 | 74,299 | 240,767 | 09/07/22 |
Melo John | President and CEO President and CEO | Aug 15 | Buy | 4.03 | 17,155 | 69,135 | 509,856 | 08/17/22 |
Melo John | President and CEO President and CEO | Jul 06 | Sell | 2.15 | 55,576 | 119,488 | 492,701 | 07/08/22 |
Hughes Anthony | CHIEF ACCOUNTING OFF.. CHIEF ACCOUNTING OFFICER | Jun 02 | Sell | 2.3401 | 6,305 | 14,754 | 106,612 | 06/03/22 |
KELSEY NICOLE | CHIEF LEGAL OFFICER-.. CHIEF LEGAL OFFICER- SECRETARY | Jun 02 | Sell | 2.3401 | 8,406 | 19,671 | 157,366 | 06/03/22 |
Kieftenbeld Hermanus | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Jun 02 | Sell | 2.34 | 34,905 | 81,678 | 266,655 | 06/03/22 |
Kung Frank | Director Director | Apr 15 | Option | 4.51 | 3,156,446 | 14,235,571 | 938,416 | 04/15/21 |